Vivo Invests $60 Million in China RNAi JV it Formed with Arrowhead
publication date: Apr 25, 2022
Vivo Capital will invest $60 million in a new JV that it formed with Arrowhead Pharma, a Pasadena, CA biotech, which will have China rights to four Arrowhead RNAi candidates. The new JV, Visirna, will pay royalties on sales to Arrowhead, but will not make any upfront payments or milestones. Vivo pledged to leverage its Greater China network to support Visirna, including recruiting a leadership team while also overseeing development, clinical, and regulatory strategies in China. In the future, Visirna will develop its own RNAi drugs and in-license others. Arrowhead owns a majority stake in Visirna. More details....
Stock Symbol: (NSDQ: ARWR)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.